Tricida (NASDAQ: TCDA)
Tricida Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Tricida Company Info
Tricida, Inc. is a pharmaceutical company. It focuses on the development and commercialization of its product, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease. The company was founded by Gerrit Klaerner and Craig Jon Hawker on May 22, 2013 and is headquartered in South San Francisco, CA.
News & Analysis
Why Tricida Stock Is Jumping Today
The drugmaker announced a stock and warrant offering.
Here's Why Tricida Shares Plummeted Today
The FDA denied the biotech's appeal, but there's still a path forward for its drug.
Here's Why Tricida Is Tanking 38.5% Today
The FDA has noted deficiencies in the application for approval of its only drug in development.
Here's What Drove Tricida 67% Higher in March
It looks like the company found an easy solution to a big problem.
Why MAG Silver, comScore, and Tricida Slumped Today
Even on a great day on Wall Street, these companies couldn't share in the good news.
Valuation
Earnings Transcripts
Tricida Inc (TCDA) Q2 2020 Earnings Call Transcript
TCDA earnings call for the period ending June 30, 2020.
Tricida Inc (TCDA) Q1 2020 Earnings Call Transcript
TCDA earnings call for the period ending March 31, 2020.
Tricida Inc (TCDA) Q4 2019 Earnings Call Transcript
TCDA earnings call for the period ending December 31, 2019.
Tricida Inc (TCDA) Q3 2019 Earnings Call Transcript
TCDA earnings call for the period ending September 30, 2019.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.